Drug Trial Radar · NCT05418348
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Aug 26, 2021
Primary completion
Feb 17, 2022
Study completion Feb 24, 2022
Sponsor
- Lead sponsor
- Grace Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, single center, randomized, two-period crossover study in healthy male and female subjects designed to evaluate the relative bioavailability (BA) and safety at steady state of two formulations of nimodipine: GTX 104 (nimodipine for intravenous \[IV\] infusion; test formulation) and nimodipine oral capsules, RS (reference formulation).
Conditions
- Aneurysmal Subarachnoid Hemorrhage
Interventions
GTX-104Drug
new formulation of nimodipine injection for IV infusion
Nimodipine CapsulesDrug
Nimodipine capsules (reference formulation)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax Day 1Time frame: Day 1 for the first dose (8:00 AM dose)
- AUC (AUCDay 3, 0-24hr)Time frame: Day 3 from 8:00 AM to 8:00 AM from 0 to 24 hr
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Research Unit
Montreal, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.